Celavie Biosciences

Celavet Animal Health

FIRST-IN-HUMAN EXPLORATORY HUMAN STEM CELL STUDY FOR PD PATIENTS

Celavie Biosciences, LLC has completed five-year follow-up in the First-in-Human Exploratory Clinical Safety Study in seven patients with Parkinson’s Disease (See Exploratory Clinical Trial). This study utilizing our human allogeneic pluripotent stem cells has demonstrated absence of stem cell related adverse events (no tumor formation, no infection and no immune rejection as well as safety of the used stereotactic technique (no surgical complications).

Based on the results of this study, Celavie Biosciences is applying to the FDA for a Phase I double blind, placebo controlled, randomized clinical trial in patients with moderate to advanced PD.

Click Here For Exploratory Clinical Trial

  • OUR TECHNOLOGY IS LIFE CHANGING
  • ADDRESSING A GLOBAL NEED
  • TREATING THE CAUSE, NOT SYMPTOMS...
  • OUR BREAKTHROUGHS OFFER HOPE
  • VETERINARY HEALTH...A FAST PATH TO MARKET
  • IN THE BUSINESS OF HOPE
  • MEASURABLE PROGRESS IN PARKINSON'S
  • OUR TECHNOLOGY IS LIFE CHANGING

    …committed to relieving suffering across the globe

  • ADDRESSING A GLOBAL NEED

    • 10+ million people have Parkinson’s disease
    • 12% of deaths result from neurological disorders
  • TREATING THE CAUSE, NOT SYMPTOMS...

    With novel therapies, cell banks and a new delivery technology

  • OUR BREAKTHROUGHS OFFER HOPE

    There are NO effective long-term treatments or cures for neurological diseases or trauma.

  • VETERINARY HEALTH...A FAST PATH TO MARKET

    • Encouraging orthopedic treatments
    • Cell characterization approved by CVM
    • Preparing for equine trials with CVM
  • IN THE BUSINESS OF HOPE

    Unleashing the natural healing power of cells

  • MEASURABLE PROGRESS IN PARKINSON'S

    • Exploratory clinical trial on 7 patients in Mexico has not revealed any lasting adverse effects or complications over a period of more than 2 years.
    • Protocol for a larger controlled single-blinded randomized trial in US is in progress.
    • Preparation of materials for IND application is in progress
  • OUR TECHNOLOGY IS LIFE CHANGING
  • OUR TECHNOLOGY IS LIFE CHANGING

    …committed to relieving suffering across the globe

Welcome to Celavie Biosciences

Welcome to Celavie Biosciences, where we are improving lives and restoring hope by changing the paradigm of stem cell technology.


Celavie Logo

At Celavie, we are developing regenerative stem cell therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system. The unmet medical needs for these conditions are significant as they result in loss of basic function or mortality.


Celavie Logo

At Celavet, a subsidiary, we are applying the same proprietary technologies for the treatment and prevention of serious veterinary diseases. Offering a faster path to market, Celavet Stem Cells have demonstrated safety and restored functions in orthopedic conditions in large and small animals.

Company:

Company:

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS).

 

Celavie

Celavet

Technology:

Technology:

Celavie produces large banks of undifferentiated cells across four mammalian lines that are grown in a specialized patented medium allowing uniform reproducible qualities and genetic stability.

 

Celavie

Celavet

Clinical Trials:

Clinical Trials:

Our approach utilizes undifferentiated allogeneic pluripotent stem cells to repair damaged tissues and restore their functions. The first-in-human exploratory pilot study in Mexico has not revealed any lasting adverse effects or complications over a period of more than five years.

 

Celavie

Celavet